Analyzing McKesson (NYSE:MCK) & Progyny (NASDAQ:PGNY)

Progyny (NASDAQ:PGNYGet Free Report) and McKesson (NYSE:MCKGet Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, earnings and profitability.

Valuation and Earnings

This table compares Progyny and McKesson”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Progyny $1.29 billion 1.54 $58.52 million $0.92 28.07
McKesson $403.43 billion 0.26 $4.76 billion $37.37 24.20

McKesson has higher revenue and earnings than Progyny. McKesson is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Progyny and McKesson’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Progyny 6.00% 15.98% 10.65%
McKesson 1.12% -253.21% 5.90%

Volatility and Risk

Progyny has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, McKesson has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Progyny and McKesson, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Progyny 0 3 9 1 2.85
McKesson 0 4 14 0 2.78

Progyny presently has a consensus price target of $33.91, indicating a potential upside of 31.33%. McKesson has a consensus price target of $973.44, indicating a potential upside of 7.64%. Given Progyny’s stronger consensus rating and higher probable upside, analysts plainly believe Progyny is more favorable than McKesson.

Insider & Institutional Ownership

94.9% of Progyny shares are held by institutional investors. Comparatively, 85.1% of McKesson shares are held by institutional investors. 9.9% of Progyny shares are held by company insiders. Comparatively, 0.1% of McKesson shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Progyny beats McKesson on 11 of the 15 factors compared between the two stocks.

About Progyny

(Get Free Report)

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

About McKesson

(Get Free Report)

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners, and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.